Cranial Electrical Stimulation (CES) as Treatment for Insomnia in Patients With Subacute Stroke
| Status: | Recruiting |
|---|---|
| Conditions: | Insomnia Sleep Studies, Neurology |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/1/2019 |
| Start Date: | February 21, 2017 |
| End Date: | December 2020 |
| Contact: | Amy Mathews, MD |
| Email: | Amy.Mathews@UTSouthwestern.edu |
| Phone: | 214-645-1719 |
Cranial Electrical Stimulation (CES) as Treatment for Insomnia in Stroke
This will be a double blinded randomized clinical trial carried out at Zale-Lipshy and
Parkland Hospital Inpatient Rehabilitation Facilities. Acute stroke patients with insomnia,
identified by the Insomnia Severity Index (ISI), and who choose to participate in this study
will be randomized to CES or sham CES. Patients who do not feel they are getting adequate
sleep but want to continue in the study will be given the option to receive the standard of
care medication as a rescue starting on the 3rd night.
Patients will receive treatment with a Fisher-Wallace CES device or Sham CES. Treatment with
CES will be for 20 minutes once a day, and the treatment period will be for 7 days. Patients
will be allowed to increase the intensity of the device from the suggested starting point of
level 2 if they feel no improvement in sleep on night 1. Groups will be monitored with a
wrist worn actigraph that records the patient's activity for the duration of the period of
study and provides data on sleep latency, time spent asleep, and sleep efficiency. The
outcome measures will be total minutes/hours of sleep, sleep efficiency and subjective
reports of drowsiness using the Karolinska Sleepiness Scale. Actigraphic data will be
collected 24 hours a day for 7 days. The total length of study will be about 24 months with a
target N of 100 consented individuals and 85 participants. Patients will be allowed to exit
the study at any time on their own choosing. To minimize loss of subjects, patients will have
the option to choose SOC rescue starting on the third night. Patients who choose the SOC
rescue will continue to be monitored with an actigraph for data collection purposes.
The investigator should discontinue study participation for a given subject or withdraw the
subject from study if he/she believes that continuation would be detrimental to the subject's
well-being. A subject can decide to withdraw from the study at any time and for any reason.
Parkland Hospital Inpatient Rehabilitation Facilities. Acute stroke patients with insomnia,
identified by the Insomnia Severity Index (ISI), and who choose to participate in this study
will be randomized to CES or sham CES. Patients who do not feel they are getting adequate
sleep but want to continue in the study will be given the option to receive the standard of
care medication as a rescue starting on the 3rd night.
Patients will receive treatment with a Fisher-Wallace CES device or Sham CES. Treatment with
CES will be for 20 minutes once a day, and the treatment period will be for 7 days. Patients
will be allowed to increase the intensity of the device from the suggested starting point of
level 2 if they feel no improvement in sleep on night 1. Groups will be monitored with a
wrist worn actigraph that records the patient's activity for the duration of the period of
study and provides data on sleep latency, time spent asleep, and sleep efficiency. The
outcome measures will be total minutes/hours of sleep, sleep efficiency and subjective
reports of drowsiness using the Karolinska Sleepiness Scale. Actigraphic data will be
collected 24 hours a day for 7 days. The total length of study will be about 24 months with a
target N of 100 consented individuals and 85 participants. Patients will be allowed to exit
the study at any time on their own choosing. To minimize loss of subjects, patients will have
the option to choose SOC rescue starting on the third night. Patients who choose the SOC
rescue will continue to be monitored with an actigraph for data collection purposes.
The investigator should discontinue study participation for a given subject or withdraw the
subject from study if he/she believes that continuation would be detrimental to the subject's
well-being. A subject can decide to withdraw from the study at any time and for any reason.
The purpose of this study is to determine if CES is a reasonable first line alternative to
the current standard of care (SOC) which relies on the use of trazodone for patients with
subacute stroke. This objective will be answered by addressing the following:
• Specific Aim 1: To determine if stroke patients with insomnia who receive CES treatment
sleep more hours than stroke patients treated with sham CES.
Hypothesis: Stroke patients with insomnia who are treated with CES will accumulate more
sleeping hours than patients who are treated with sham CES.
• Specific Aim 2: To determine if stroke patients with insomnia who receive CES treatment
have better sleep efficiency than stroke patients treated with sham CES.
Hypothesis: Stroke patients with insomnia who are treated with CES will demonstrate
significantly better sleep efficiency than stroke patients treated with shame CES.
The study will take place at Zale Lipshy Hospital in Dallas, TX. The study will enroll 85
stroke patients who score 7 or higher on the Insomnia Severity Scale. Patients will be
randomized to a control group or CES treatment group. Patients will receive CES or sham CES
for 7 days after a 24-hour washout period. Objective and subjective sleep assessments will be
conducted daily during the 7-day study period. Endpoints will be total time spent sleeping,
sleep efficiency and daytime drowsiness.
The known risks of CES are minimal and mild in nature. They include potential for headache,
irritation at the site of electrode placement and dizziness. These adverse reactions are rare
and in most cases there are no immediate or delayed side effects.
This randomized controlled trial is designed to meet two study objectives related to quality
of sleep and daytime drowsiness.
Demographic data will be collected from the hospital record and will include age, gender,
type of stroke, self-reported history of insomnia or other sleep disorder, prior use of sleep
medications, in-hospital use of sleep medications, co-morbid medical conditions.
Patients admitted to inpatient rehabilitation (IPR) who consent to the study will undergo an
overnight washout period before initiation of CES or sham treatment. This allows for any
sleep medication they might have received while in acute care to be metabolized and leave
their system. On their admission day, day 0 (d0) patients will be asked if they want to
participate in our study. If they choose to participate and meet medical inclusion criteria,
they will be tested with ISI. Patients who meet the full criteria will not receive sleep
medication or CES on their first night.
The study will begin on day 1 (d1) with the patient receiving 20 minutes of CES/sCES in the
morning. This time will be distraction free without the entrance of laboratory technicians,
nurses, housekeeping or other staff members. When this period is complete, they will
participate in usual care. At midday they will be asked to complete the Karolinska Sleepiness
Scale (KSS). The patient will wear the actigraph throughout the study. This procedure will be
repeated for 7 treatment days. All procedures will be carried out by research team members or
a trained nurse.
The intensity of the CES will begin on setting 2, standard setting recommended by the device
manufacturer, and the patient will have the option to increase the intensity to setting 3 on
the second treatment day if they feel they did not receive any benefit from the device.
If the patient does not feel they are getting adequate sleep the patient may choose to opt
out of CES/sCES treatment and receive the standard of care medication for the remainder of
the study. Patients who choose the SOC rescue will continue to be monitored with the
actigraph. A patient may choose to leave the study at any time.
Information on side effects for the CES treatment will be collected during the 7 days of the
study.
Methods of assigning patients to treatment groups and blinding Patients will be randomized to
the active or sham treatment group using an online randomizer, Research randomizer
(www.randomizer.org). A list of random numbers will be generated prior to the study. Patients
will be assigned a random number in the order that the generator produces. All even patients
will be assigned to the control group; odd numbered patients will be assigned to the
treatment group.
Procedural responsibilities and oversight Nursing staff will be educated how to administer
the CES and asked to help distribute and collect the Karolinska Sleepiness Scale
questionnaire. Photos of proper placement and instructions will be posted in subjects' rooms
for reference. Researchers affiliated with this project will apply and remove the actigraph
watches and be responsible for data acquisition, cleaning and charging of the devices.
Researchers affiliated with the study will be responsible for ensuring CES is delivered to
the appropriate patients on the days required per protocol.
Verbal recruitment process will be used for the study. The attending and resident physicians
will be educated about the study and asked to identity patients who may be appropriate. A
member of the research team will explain the risks, benefits and rationale for the study to
patients who meet inclusion criteria. Patients will be enrolled when they arrive on the
rehabilitation floor if they choose to participate. Consent will be attained via a written
document in the subject's primary language (English or Spanish).
The research team will protect subjects' privacy by conducting all study related verbal
interactions with the subject in a closed room, such as the patient's room. For
confidentiality, each subject screened will be assigned a unique identification number (ID#).
Subjects will only be identified by the unique ID # in the data. No demographic data or
personal information will be used to identify subjects. This unique ID# will be linked to
subject name and will be kept in a locked file cabinet, accessible only to the research team.
Only the research team will have access to the data. All data for presentations and
publications will be reported as mean ± standard error of means. Investigators will educate
faculty and residents on each floor about the study to maintain privacy and compliance.
Sample size was calculated based on several studies that measured the number of hours that
subacute rehabilitation patients sleep in an inpatient hospital setting. Alpha levels for
error probability were set at .05 for a two-tailed test with 80% power to detect a difference
between means of control group compared to CES treatment group.
Descriptive statistics will be used to determine differences between CES and sCES treatment
groups. A T-test will be used to determine if sleep time means differ between groups (p≤
.05). A chi square analysis will be used to compare data collected from the Karolinska
Sleepiness Scale. A non-parametric test will be used if data is not able to demonstrate
normal distribution.
the current standard of care (SOC) which relies on the use of trazodone for patients with
subacute stroke. This objective will be answered by addressing the following:
• Specific Aim 1: To determine if stroke patients with insomnia who receive CES treatment
sleep more hours than stroke patients treated with sham CES.
Hypothesis: Stroke patients with insomnia who are treated with CES will accumulate more
sleeping hours than patients who are treated with sham CES.
• Specific Aim 2: To determine if stroke patients with insomnia who receive CES treatment
have better sleep efficiency than stroke patients treated with sham CES.
Hypothesis: Stroke patients with insomnia who are treated with CES will demonstrate
significantly better sleep efficiency than stroke patients treated with shame CES.
The study will take place at Zale Lipshy Hospital in Dallas, TX. The study will enroll 85
stroke patients who score 7 or higher on the Insomnia Severity Scale. Patients will be
randomized to a control group or CES treatment group. Patients will receive CES or sham CES
for 7 days after a 24-hour washout period. Objective and subjective sleep assessments will be
conducted daily during the 7-day study period. Endpoints will be total time spent sleeping,
sleep efficiency and daytime drowsiness.
The known risks of CES are minimal and mild in nature. They include potential for headache,
irritation at the site of electrode placement and dizziness. These adverse reactions are rare
and in most cases there are no immediate or delayed side effects.
This randomized controlled trial is designed to meet two study objectives related to quality
of sleep and daytime drowsiness.
Demographic data will be collected from the hospital record and will include age, gender,
type of stroke, self-reported history of insomnia or other sleep disorder, prior use of sleep
medications, in-hospital use of sleep medications, co-morbid medical conditions.
Patients admitted to inpatient rehabilitation (IPR) who consent to the study will undergo an
overnight washout period before initiation of CES or sham treatment. This allows for any
sleep medication they might have received while in acute care to be metabolized and leave
their system. On their admission day, day 0 (d0) patients will be asked if they want to
participate in our study. If they choose to participate and meet medical inclusion criteria,
they will be tested with ISI. Patients who meet the full criteria will not receive sleep
medication or CES on their first night.
The study will begin on day 1 (d1) with the patient receiving 20 minutes of CES/sCES in the
morning. This time will be distraction free without the entrance of laboratory technicians,
nurses, housekeeping or other staff members. When this period is complete, they will
participate in usual care. At midday they will be asked to complete the Karolinska Sleepiness
Scale (KSS). The patient will wear the actigraph throughout the study. This procedure will be
repeated for 7 treatment days. All procedures will be carried out by research team members or
a trained nurse.
The intensity of the CES will begin on setting 2, standard setting recommended by the device
manufacturer, and the patient will have the option to increase the intensity to setting 3 on
the second treatment day if they feel they did not receive any benefit from the device.
If the patient does not feel they are getting adequate sleep the patient may choose to opt
out of CES/sCES treatment and receive the standard of care medication for the remainder of
the study. Patients who choose the SOC rescue will continue to be monitored with the
actigraph. A patient may choose to leave the study at any time.
Information on side effects for the CES treatment will be collected during the 7 days of the
study.
Methods of assigning patients to treatment groups and blinding Patients will be randomized to
the active or sham treatment group using an online randomizer, Research randomizer
(www.randomizer.org). A list of random numbers will be generated prior to the study. Patients
will be assigned a random number in the order that the generator produces. All even patients
will be assigned to the control group; odd numbered patients will be assigned to the
treatment group.
Procedural responsibilities and oversight Nursing staff will be educated how to administer
the CES and asked to help distribute and collect the Karolinska Sleepiness Scale
questionnaire. Photos of proper placement and instructions will be posted in subjects' rooms
for reference. Researchers affiliated with this project will apply and remove the actigraph
watches and be responsible for data acquisition, cleaning and charging of the devices.
Researchers affiliated with the study will be responsible for ensuring CES is delivered to
the appropriate patients on the days required per protocol.
Verbal recruitment process will be used for the study. The attending and resident physicians
will be educated about the study and asked to identity patients who may be appropriate. A
member of the research team will explain the risks, benefits and rationale for the study to
patients who meet inclusion criteria. Patients will be enrolled when they arrive on the
rehabilitation floor if they choose to participate. Consent will be attained via a written
document in the subject's primary language (English or Spanish).
The research team will protect subjects' privacy by conducting all study related verbal
interactions with the subject in a closed room, such as the patient's room. For
confidentiality, each subject screened will be assigned a unique identification number (ID#).
Subjects will only be identified by the unique ID # in the data. No demographic data or
personal information will be used to identify subjects. This unique ID# will be linked to
subject name and will be kept in a locked file cabinet, accessible only to the research team.
Only the research team will have access to the data. All data for presentations and
publications will be reported as mean ± standard error of means. Investigators will educate
faculty and residents on each floor about the study to maintain privacy and compliance.
Sample size was calculated based on several studies that measured the number of hours that
subacute rehabilitation patients sleep in an inpatient hospital setting. Alpha levels for
error probability were set at .05 for a two-tailed test with 80% power to detect a difference
between means of control group compared to CES treatment group.
Descriptive statistics will be used to determine differences between CES and sCES treatment
groups. A T-test will be used to determine if sleep time means differ between groups (p≤
.05). A chi square analysis will be used to compare data collected from the Karolinska
Sleepiness Scale. A non-parametric test will be used if data is not able to demonstrate
normal distribution.
Inclusion Criteria:
1. Written informed consent must be obtained.
2. Patients must be admitted to inpatient rehab.
3. Patients must have a documented acute stroke (ischemic, hemorrhagic or embolic).
4. Patients must have at least one fully functional arm which can be used to record
actigraph data via a wrist worn actigraph device.
5. Subjects must Score a 7 or higher on the ISI.
6. Patients must be able to communicate consent and/or desire to discontinue the study.
Exclusion Criteria 1. Demand or sensing type cardiac pacemaker. 2. Known uncontrolled
seizure disorder. 3. Current history of vertigo. 4. Need for continuous O2. 5. Inability to
communicate or provide consent. 6. Restricted use or absence of both arms.
We found this trial at
1
site
Click here to add this to my saved trials
